Cancer
December 18, 2023
Manish Agrawal, Yvan Beaussant, Sarah Shnayder et al.
73 citations
Abstract Background Depression is common in patients with cancer and is associated with lower treatment adherence and reduced quality of life. Antidepressants and psychotherapy have limited success in improving depression among patients with cancer. This study explored the safety, feasibility, and efficacy of psilocybin‐assisted therapy in patients with cancer and major depressive disorder....
Cancer
December 18, 2023
Yvan Beaussant, Kabir Nigam, Zachary Sager et al.
22 citations
Abstract Background The present study explored the acceptability of psilocybin‐assisted group therapy from the perspective of patients with cancer and depression who participated in a clinical trial assessing the safety and efficacy of this novel intervention. Methods Guided by the conceptual framework of acceptability, the authors conducted semi‐structured interviews with participants of the...
Frontiers in Psychiatry
December 6, 2023
Elliot Marseille, Manish Agrawal, Paul Thambi et al.
40 citations
Objective To compare group and individual psychedelic-assisted therapy in terms of clinician time, costs and patient access. Methods Using 2023 data from two group therapy trial sites, one using 3,4-Methylenedioxymethamphetamine (MDMA) to treat posttraumatic stress disorder (PTSD), and one using psilocybin to treat major depressive disorder (MDD), we compared overall variable costs, clinician...
Journal of Palliative Medicine
August 17, 2023
Robert Gramling, Emily Bennett, Keith Curtis et al.
6 citations
Context: Measuring therapeutic connection during psilocybin-assisted therapy is essential to understand underlying mechanisms, inform training, and guide quality improvement. Purpose: To evaluate the feasibility of directly observing indicators of therapeutic connection during psilocybin administration encounters. Methods: We evaluated audio and video data from a recent clinical trial for...
Journal of Clinical Oncology
June 1, 2023
Manish Agrawal, Sarah Shnayder, Heather Honstein et al.
2 citations
12021 Background: Up to 25% of people living with cancer have depression. Existing psychological interventions have limited efficacy in treating depression. Psilocybin, a 5-hydroytrptamintergic psychedelic, coupled with group therapy is safe and effective in ameliorating symptoms of depression (Agrawal et al, ASCO 2022). Response to psilocybin treatment was observed in 83.3% of patients at 8...
JAMA Oncology
April 13, 2023
Manish Agrawal, Ezekiel Emanuel, Brian D. Richards et al.
48 citations
This nonrandomized controlled trial used a 1-to-1 therapist-to-patient ratio to administer psilocybin to groups of patients with cancer who were diagnosed with major depression disorder to create a scalable, rapidly effective depression treatment.
Journal of Clinical Oncology
June 1, 2022
Manish Agrawal, Paul Thambi, Sarah Shnayder
3 citations
12097 Background: More than 17 million people in the U.S. live with cancer and up to 25% of them have major depression. Depression leads to lower treatment adherence, reduced quality of life, and higher rates of mortality in cancer. Yet, interventions used to treat depression in patients with cancer have limited success. Prior trials using psilocybin to treat anxiety and depression associated...